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Key Points
•More than half of pa-
tients with PV or ET
harbor DNA mutations/
variants other than
JAK2/CALR/MPL.
• The presence of some
of these mutations ad-
versely affects overall,
leukemia-free, or
myelofibrosis-free
survival.
Polycythemia vera (PV) is characterizedby JAK2 and essential thrombocythemia (ET) by JAK2,
calreticulin (CALR), and myeloproliferative leukemia virus oncogene (MPL) mutations; we
describe the occurrence and prognostic relevance of DNA sequence variants/mutations other
than JAK2/CALR/MPL. A myeloid neoplasm–relevant 27-gene panel was used for next-
generation sequencing of bonemarrow orwhole bloodDNA and conventional toolswere used
for analysis. “Adverse variants/mutations” were identified by age-adjusted multivariable
analysis of impact on overall, leukemia-free, or myelofibrosis-free survival. Fifty-three
percent of 133 Mayo Clinic patients with PV and 53% of 183 with ET harbored 1 or more
sequence variants/mutations other than JAK2/CALR/MPL; the most frequent were TET2 and
ASXL1. “Adverse variants/mutations” in PV included ASXL1, SRSF2, and IDH2 and in ET
SH2B3, SF3B1, U2AF1, TP53, IDH2, and EZH2; combined prevalence was 15% and 15%,
respectively. Adverse variants/mutations were associated with inferior survival in both PV
(median, 7.7 vs 16.9 years) and ET (median, 9 vs 22 years) and the effect was independent of
conventional prognostic models with respective hazard ratio (95% confidence interval) of
2.8 (1.5-5.1) and 2.6 (1.4-4.8); these observations were validated in 215 Italian patients with PV
and 174 with ET. In both Mayo Clinic and Italian cohorts, leukemic or fibrotic progression
was also predicted by adverse variants/mutations. Number of mutations did not provide
additional prognostic information. We conclude that targeted deep sequencing in PV and ET
allows for genetic risk stratification that is independent of clinically derived prognostic
models.
Introduction
Despite seminal descriptions of novel1-6 and other less specific7,8 mutations in the last 10 years, the
molecular pathogenesis of myeloproliferative neoplasms (MPNs) remains incompletely understood;
however, there has been increasing use of these mutations in diagnostics and disease prognostication.9
Mutations in MPNs are operationally classified into those that involve JAK2, calreticulin (CALR), and
myeloproliferative leukemia virus oncogene (MPL) and those that involve other genes, such as additional
sex combs like transcriptional regulator 1 (ASXL1).9 The former are believed to be “driver”mutations and
are now formally integrated into the World Health Organization (WHO) diagnostic criteria for
polycythemia vera (PV; 98% JAK2 mutational frequency), essential thrombocythemia (ET; 60% JAK2,
22% CALR, and 3%MPL mutational frequency) and primary myelofibrosis (PMF).10 In terms of disease
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prognostication, type 1/type 1–like CALR mutations have been
associated with superior survival in PMF11,12 and JAK2 mutations
with thrombosis in ET.13
The prognostic contribution of mutations other than JAK2, CALR, or
MPL has been demonstrated in PMF, where ASXL1, serine/arginine-
rich splicing factor 2 (SRSF2), isocitrate dehydrogenase 1 or 2
(IDH1/2), and enhancer of zeste 2 polycomb repressive complex 2
subunit (EZH2) were identified as being unfavorable to survival.7
More recent studies have suggested the prognostic relevance of not
only the specific type but also the number of mutations.8,14 These
observations are noteworthy considering the increasing application
of next-generation sequencing (NGS) technology in clinical practice.
In the current study, we used custom-designed targeted sequencing
of 27 myeloid neoplasm–relevant genes that are also often included
in most commercially available NGS gene panels used in myeloid
cancer. Our main objective was to determine the prognostic and
phenotypic relevance of sequence variants/mutations, other than
JAK2, CALR and MPL, in PV and ET.
Methods
The current study was approved by the institutional review boards
of the Mayo Clinic and the University of Florence, Florence, Italy.
Diagnoses and treatment approaches were in accordance with what
was considered standard of care at the time of initial diagnosis.15
Targeted capture assays for Mayo Clinic patients (the main study
cohort) were carried out on bone marrow or whole-blood DNA for the
following genes: TET2, DNMT3A, IDH1, IDH2, ASXL1, EZH2,
SUZ12, SRSF2, SF3B1, ZRSR2, U2AF1, PTPN11, TP53, SH2B3,
RUNX1, CBL, NRAS, JAK2, CSF3R, FLT3, KIT, CALR, MPL,
NPM1, CEBPA, IKZF1, and SETBP1. Additional details regarding
NGS analysis are outlined in the supplemental Methods, which also
includes the methods used in the validation cohort from the University
of Florence. Prognostic evaluation of sequence variants/mutations
considered both the “number” of sequence variants/mutations and
the specific genes affected. “Adverse sequence variants/mutations”
were identified by age-adjusted multivariable analysis of their impact on
overall survival or multivariable analysis of impact on leukemia-free or
myelofibrosis-free survival.
All statistical analyses considered clinical and laboratory parame-
ters obtained at time of diagnosis. Differences in the distribution of
continuous variables between categories were analyzed by either
the Mann-Whitney or the Kruskal-Wallis test. Patient groups with
nominal variables were compared by x2 test. Survival analysis was
considered from the date of diagnosis to date of death or last
contact; because of the considerable effect of age on survival, univar-
iate analysis for overall survival was adjusted for age. Leukemia-
free and myelofibrosis-free survival calculations considered the
transformation events as the uncensored variable. Survival curves
were prepared by the Kaplan-Meier method and compared by the
log-rank test. The Cox proportional hazard regression model was
used for multivariable analysis. P values ,.05 were considered
significant. All analyses were conducted using the Stat View (SAS
Institute, Cary, NC).
Results
A total of 316MayoClinic patients with PV (n5 133) or ET (n5 183)
were evaluated; Tables 1 and 2 outline the presenting clinical and
laboratory details. “Driver”mutation distribution was 98% JAK2 for
PV and 52% JAK2, 26% CALR, and 4% MPL for ET. According to
conventional prognostic models,16,17 survival risk distribution at time
of diagnosis was 45% high, 26% intermediate, and 29% low for PV,
and 21% high, 39% intermediate, and 40% low for ET. Median
follow-up was 10.4 years for PV and 10.1 years for ET. The respective
numbers of documented deaths, leukemic transformations, and
fibrotic progressions were, for PV, 62 (47%), 7 (5.3%), and 14 (11%)
and for ET 61 (33%), 6 (3.3%), and 27 (15%).
Prevalence and cosegregation of sequence
variants/mutations
Sequence variants/mutations other than JAK2,CALR, orMPLwere
seen in 70 patients with PV (52.6%) and 96 with ET (52.5%)
(Figure 1); supplemental Table 1 provides additional information on
specific variants/mutations. The respective percentages of patients
with 1, 2, or $3 sequence variants/mutations were 30%, 20%,
and 3% for PV and 41%, 8%, and 4% for ET. The most frequent
sequence variants/mutations in both disorders were TET2 and
ASXL1 (Figure 1). There were no significant associations between
JAK2/CALR/MPL mutational status and number or type of other
sequence variants/mutations. Among the most frequent sequence
variants/mutations, ASXL1 in ET cosegregated with EZH2 (P, .001),
IDH2 (P 5 .004), and RUNX1 (P 5 .002) and in PV with IDH2
(P 5 .003) and KIT (P 5 .02); TET2 in PV cosegregated with
SH2B3 (P 5 .01).
Phenotypic correlations of sequence
variants/mutations
Phenotypic correlations were examined for sequence variants/mutations
with a recurrence rate of at least 5% (Figure 1). Parameters examined
for possible association included age, sex, risk category,16,17 karyotype,
thrombosis history, leukocyte count, hemoglobin level, platelet count,
palpable splenomegaly, pruritus, andmicrovascular symptoms. Themost
noteworthy association was between TET2 variants/mutations and
thrombosis in ET (P5 .01), which was independent of both age and
JAK2/CALR/MPL mutational status; relative risk on age-adjusted
multivariable analysis was 3.4 (95% confidence interval [CI], 1.4-8.4),
compared with 4.8 (95% CI, 1.6-14.2) for JAK2 vs CALR. However,
such association was not evident in either PV or an external cohort
of 174 Italian patients with ET seen at the University of Florence
(P5 .58). In ET, TET2 and SF3B1 variants/mutations were associated
with older age (P 5 .04 and 0.04, respectively), SF3B1 with higher
platelet count (P 5 .02), and ASXL1 with palpable splenomegaly
(P 5 .009). In PV, the only association noted was between SH2B3
variants/mutations and palpable splenomegaly (P 5 .045).
Prognostic relevance of sequence
variants/mutations in PV
Median survival of the 133MayoClinic patients with PVwas 14.2 years.
Age-adjusted univariate analysis identifiedSRSF2,ASXL1, and IDH2
variants/mutations as being significantly associated with inferior
survival; ASXL1 (hazard ratio [HR], 2.2; 95%CI, 1.1-4.3) andSRSF2
(HR, 6.1; 95% CI, 2.0-19.2) remained significant on multivariable
analysis. For leukemia-free and myelofibrosis-free survival, univariate
analysis showed significant associations with SRSF2, IDH2, and
RUNX1 for the former and with SRSF2 and RUNX1 for the latter; on
multivariable analysis, SRSF2 (HR, 74.5, 95% CI, 4.4-1261.7) and
IDH2 (HR, 55.5; 95% CI, 3.5-887.4) remained significant for
leukemia-free survival and SRSF2 (HR, 27.2; 95% CI, 2.7-274.3)
for myelofibrosis-free survival.
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Based on their above-outlined independent impact on overall, leukemia-
free, or myelofibrosis-free survival, ASXL1, SRSF2, and IDH2 variants/
mutations were identified as being “adverse” in PV and at least 1 of the
3 was present in 20 of the 133 patients (15%). Patients with adverse
variants/mutations displayed significantly worse survival when com-
pared with both patients with other sequence variants/mutations (HR,
2.1; 95%CI, 1.1-4.1) and those without any sequence variant/mutation
(HR, 2.2; 95% CI, 1.2-4.2; Figure 2A); there was no difference in
survival between patients with other sequence variants/mutations and
those without any sequence variant (P 5 .92).
The difference in survival between patients with and without adverse
variants/mutations was independent of age, the IWG prognostic
model for PV,17 and karyotype, with respective HRs (95% CIs) of
2.7 (1.5-4.9), 2.8 (1.5-5.1), and 2.4 (1.2-4.6). Additional multivariable
analysis that included the individual variables used in the IWG
prognostic model17 confirmed the independent prognostic contri-
bution of adverse variants/mutations (HR, 3.0; 95% CI, 1.6-5.5),
along with age (HR, 5.6; 95% CI, 3.1-10.0 for age $65 years) and
leukocytosis (HR, 2.0; 95% CI, 1.2-3.5 for leukocyte count $15 3
109/L); venous thrombosis was no longer significant in the partic-
ular multivariable model (P 5 .32). The presence of adverse
variants/mutations was also associated with shorter leukemia-
free (Figure 3A; P 5 .02; HR, 5.6; 95% CI, 1.3-25.4) and
myelofibrosis-free (Figure 4A; P 5 .11; HR, 2.5; 95% CI, 0.8-8.1)
survivals, although the latter did not reach significance.
Patients with 3 sequence variants/mutations (n 5 4) had signif-
icantly worse survival, compared with those with 2 (n5 26; P5 .04),
1 (n 5 40; P 5 .003), or no (n 5 63; P 5 .003) sequence variant/
mutation, whereas there was no difference in survival among the
latter 3 groups (P5 .29), especially after adjusting for age (P5 .72).
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Figure 1. Twenty-seven–gene panel DNA sequence variants in Mayo Clinic patients with PV (n 5 133) and ET (n 5 183). (A,C) Individual variant/mutational
cosegregation plot for both PV and ET. Each column represents 1 of the sequenced subjects. Variant/mutations are depicted by representative colored bars. Red, Variants
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totals in PV and ET ranked by gene and corresponding overall frequency percentage.
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Furthermore, the shorter survival seen in the 4 patients with 3
sequence variants/mutations was fully accounted for by the presence
of adverse variants/mutations in all of them.
Validation of prognostic relevance of adverse
sequence variants/mutations in PV
The observations from the Mayo Clinic patients were validated in an
external cohort of 215 Italian patients with PV (Tables 1 and 2),
followed for a median of 11.9 years and with 84 deaths (39%), 55
fibrotic progressions (26%), and 6 leukemic transformations (3%);
the particular cohort was enriched for patients who experienced
fibrotic progression, in order to increase the power for molecular
prediction for fibrotic transformation. In multivariable analysis, the
unfavorable survival effect of adverse variants/mutations on survival
(Figure 2B; HR, 2.6; 95% CI, 1.5-4.6) was independent of the IWG
prognostic model for PV17; HRs (95% CIs) were 2.3 (1.3-4.1)
for adverse variants/mutations and 3.6 (1.7-7.8) for high- or
intermediate-risk category. Adverse variants/mutations also affected
myelofibrosis-free survival (Figure 4B), but the effect on leukemia-free
survival was not significant (Figure 3B). Multivariable analysis
confirmed the individual prognostic contribution of ASXL1 (HR,
2.41; 95% CI, 1.3-4.5) and SRSF2 (HR, 3.84; 95% CI, 1.2-12.6)
variants/mutations to overall survival and ASXL1 to myelofibrosis-free
survival (HR, 1.9; 95% CI, 1.2-3.6).
Prognostic relevance of sequence variants/mutations
in ET
Median survival of the 183 Mayo Clinic patients with ET was 19.9
years. Age-adjusted univariate analysis identified IDH2, EZH2, and
SH2B3 variants/mutations as significant risk factors for survival;
SH2B3 (HR, 3.0; 95% CI, 1.03-8.2) and IDH2 (HR, 22.1; 95% CI,
2.8-176.9) remained significant on multivariable analysis. For
leukemia-free and myelofibrosis-free survival, univariate analysis
showed significant associations with TP53, EZH2, SRSF2, and
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Figure 2. Overall survival curves. (A) Survival in 133 Mayo Clinic patients with PV stratified by the presence or absence of “adverse” (ASXL1, SRSF2, IDH2) or “other”
(TET2, SH2B3, SF3B1, SETBP1, DNMT3A, CSF3R, CEBPA, SUZ12, ZRSR2, KIT, RUNX1, FLT3, CBL, and TP53) DNA sequence variants/mutations. (B) Survival in 215 Italian
patients with PV stratified by the presence or absence of adverse (ASXL1, SRSF2, IDH2) variants/mutations. (C) Survival in 183 Mayo Clinic patients with ET stratified by the
presence or absence of “adverse” (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) or “other” (TET2, ASXL1, PTP11, SUZ12, ZRSR2, CBL, CEBPA, CSF3R, DNMT3A, SRSF2,
FLT3, KIT, NRAS, RUNX1, SETBP1) sequence variants/mutations. (D) Survival in 174 Italian patients with ET stratified by the presence or absence of adverse (SH2B3, IDH2,
SF3B1, U2AF1, EZH2, TP53) variants/mutations.
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IDH2 variants/mutations for the former and with SF3B1 and
U2AF1 for the latter; on multivariable analysis, TP53 (HR, 82.8;
95% CI, 7.5-916) and EZH2 (HR, 146.8; 95% CI, 11.1-1935.6)
remained significant for leukemia-free survival and SF3B1 (HR,
8.1; 95% CI, 2.5-25.8) and U2AF1 (HR, 30.3; 95% CI, 3.4-271.0)
for myelofibrosis-free survival.
Based on their above-outlined independent impact on overall,
leukemia-free, or myelofibrosis-free survival, SH2B3, IDH2, U2AF1,
SF3B1, EZH2, and TP53 variants/mutations were identified as
being “adverse” and at least 1 of them was present in 27 (14.8%) of
the 183 patients with ET. Patients with adverse variants/mutations
displayed significantly worse overall survival, when compared with
both patients with other sequence variants/mutations (HR, 4.3;
95% CI, 2.2-8.5) and those without any sequence variant/mutation
(HR, 7.0; 95% CI, 3.5-14.1; Figure 2C). In univariate analysis,
patients with other sequence variants/mutations also showed signifi-
cantly worse survival, when compared with patients without any
sequence variant/mutation (HR, 2.0; 95% CI, 1.1-3.7); however, in
multivariable analysis that included age, the difference in survival
remained significant for patients with adverse variants/mutations (HR,
3.4; 95% CI, 1.6-7.0) but not for those with other sequence variants/
mutations (HR, 1.5; 95% CI, 0.8-2.8). The presence of adverse
variants/mutations was also associated with significantly shorter
leukemia-free (Figure 3C; HR, 36.2; 95% CI, 3.8-347.9) and
myelofibrosis-free (Figure 4C; HR, 6.6; 95% CI, 2.6-16.4) survivals.
Patients without any sequence variant/mutation (n 5 87) had
significantly longer survival when compared with those with 3 or 4
(n 5 7; P , .0001) or 1 (n 5 75; P 5 .0009) sequence variant but
not to those with 2 sequence variants (n 5 14; P 5 .28). However,
when analysis was repeated after adjusting for age and excluding
patients with adverse variants/mutations (n 5 27), the survival
impact of the number of mutations was no longer evident (P5 .21);
6 of the 7 patients with 3 or more sequence variants also had
adverse variants. In other words, in both ET and PV, patients with
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Figure 3. Leukemia-free survival curves. (A) Leukemia-free survival in 133 Mayo Clinic patients with PV stratified by the presence or absence of “adverse” (ASXL1,
SRSF2, IDH2) DNA sequence variants/mutations. (B) Leukemia-free survival in 215 Italian patients with PV stratified by the presence or absence of adverse variants/mutations.
(C) Leukemia-free survival in 183 Mayo Clinic patients with ET stratified by the presence or absence of “adverse” (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) sequence
variants/mutations. (D) Leukemia-free survival in 174 Italian patients with ET stratified by the presence or absence of adverse sequence variants/mutations.
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multiple sequence variants were older and more likely to harbor
adverse variants, thus giving the appearance of unfavorable prog-
nostic impact during unadjusted survival analysis.
The difference in survival between patients with and without adverse
variants/mutations was independent of age (HR, 2.6; 95%CI, 1.4-4.8),
IWG prognostic model for ET16 (HR, 2.6; 95% CI, 1.4-4.8), and
karyotype (HR, 4.7; 95% CI, 2.4-9.2). Additional multivariable analysis
that included the individual variables used in the IWG prognostic
model16 confirmed the independent prognostic contribution of adverse
variants/mutations (HR, 2.4; 95%CI, 1.2-4.7), along with age (HR, 3.2;
95% CI, 1.6-6.2 for age $60 years) and leukocytosis (HR, 2.1; 95%
CI, 1.2-3.7 for leukocyte count $11 3 109/L); thrombosis was no
longer significant in the particular multivariable model (P 5 .68).
Validation of prognostic relevance of adverse
sequence variants/mutations in ET
The observations from the Mayo Clinic patients were validated in an
external cohort of 174 Italian patients with ET (Tables 1 and 2)
followed for a median of 13 years and with 62 deaths (36%), 58 fibrotic
progressions (33%), and 8 leukemic transformations (5%); the particular
cohort was enriched for patients who experienced fibrotic progression,
in order to increase the power for molecular prediction for myelofibrosis-
free survival. In multivariable analysis, the unfavorable survival effect of
adverse variants/mutations (Figure 2D; HR, 2.5; 95% CI, 1.5-4.4) was
independent of the IWG prognostic model for ET16: HRs (95% CIs)
were 2.0 (1.1-3.6) for adverse variants, 3.5 (1.6-7.7) for the intermediate-
risk category, and 8.7 (3.6-21.0) for the high-risk category. Multivariable
analysis confirmed the individual prognostic contribution of U2AF1 to
overall (HR, 2.9; 95%CI, 1.1-8.7) and myelofibrosis-free (HR, 3.2; 95%
CI, 1.1-9.0) survival and that of TP53 to leukemia-free survival (HR, 7.3;
95% CI, 1.5-35.9). Adverse variants/mutations also affected leukemia-
free (Figure 3D; HR, 6.7; 95% CI, 1.6-28.1) and myelofibrosis-free
survival (Figure 4D; HR, 2.6; 95% CI, 1.4-4.5).
Discussion
The revelation, in the current study, of DNA sequence variants/
mutations, other than JAK2/CALR/MPL, in the majority of patients
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Figure 4. Myelofibrosis-free survival curves. (A) Myelofibrosis-free survival in 133 Mayo Clinic patients with PV stratified by the presence or absence of “adverse” (ASXL1,
SRSF2, IDH2) DNA sequence variants/mutations. (B) Myelofibrosis-free survival in 215 Italian patients with PV stratified by the presence or absence of adverse variants/mutations.
(C) Myelofibrosis-free survival in 183 Mayo Clinic patients with ET stratified by the presence or absence of “adverse” (SH2B3, IDH2, SF3B1, U2AF1, EZH2, TP53) sequence
variants/mutations. (D) Myelofibrosis-free survival in 174 Italian patients with ET stratified by the presence or absence of adverse sequence variants/mutations.
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with PV or ET is consistent with the results from a smaller previous
study that showed the presence of proven mutations in 44% and
29% of the respective diseases.8 The current study identifies
prognostically important specific sequence variants/mutations and
demonstrates the subsidiary role, in this regard, of the “number” of
mutations.
The detrimental nature of some of the adverse variants identified in
the current study has also been recognized in other chronic myeloid
malignancies, including PMF (ASXL1, SRSF2, EZH2, IDH1/2,
U2AF1),7,18 chronic myelomonocytic leukemia (ASXL1),19 and
myelodysplastic syndromes (ASXL1, EZH2, TP53, SRSF2).20,21
Similarly, TP53, IDH2, SRSF2, and SH2B3 mutations were
previously found to be overrepresented in blast-phase MPNs.8,22,23
In this regard, the possible leukemogenic cooperation of mutant
JAK2 with IDH1/2 mutations has previously been clinically
suggested24 and that of TP53 loss with mutant JAK2 demonstrated
in vivo.23 Consistent with the latter observation, all 5 TP53-mutated
patients with ET, in the current study, were also JAK2-mutated, and
leukemic transformation in another study8 was temporally linked to
the consequent loss of the wild-type TP53 allele in TP53-mutated
patients.
The observations from the current study are practically relevant and
timely considering the increasing use of targeted NGS in routine
myeloid cancer practice. We show that the occurrence of sequence
variants/mutations other than JAK2/CALR/MPL, in patients with
PV or ET, is not infrequent and neither the type nor number of
genes involved is necessarily detrimental to disease outcome,
unless it involves specific genes with prognostic relevance. On the
other hand, patients with adverse variants/mutations, regardless
of their conventional risk category, might require closer monitor-
ing. In this regard, the current study suggests the possibility of
refining clinically derived prognostic models by the incorporation
of molecular information.
Additional studies are warranted in order to refine and possibly
expand the pool of clinically relevant DNA sequence variants/
mutations that could be targeted by NGS. Such a strategy would
ideally also include sequence variants/mutations that identify patients
with increased risk of thrombosis. In this regard, the discrepant
results between the Mayo Clinic and Florence patient cohorts, in
regards to the possible association between TET variants/mutations
and thrombosis in ET, remains unexplained and deserves further
investigation.
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